RxDoctor Payments Data

Amadou Camara, MD

Neurology · Durham, NCNPI 1083102453

Payments from drug & device makers

$23,515in general payments, 2019–2025

Across 390 payments — averaging $60.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$15K
  • UCB, Inc.$1K
  • AbbVie$558
  • SK Life Science, Inc.$464
  • Pfizer$461
  • Jazz Pharmaceuticals Inc.$406
  • plus $5K from 43 others

What the payments were for

  • Speaking & faculty fees$7,50032%
  • Travel & lodging$5,56624%
  • Food & beverage$10,44944%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,515 in reported general payments places this provider in the 75th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$104,038
Medicare patients
262
Services billed
13,923

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)17$87,063
XcopriCenobamate32$39,171
Aimovig AutoinjectorErenumab-Aooe26$34,300
BriviactBrivaracetam21$32,315
ValtocoDiazepam20$27,975
VimpatLacosamide18$24,049
Nurtec OdtRimegepant Sulfate11$11,599
EliquisApixaban19$10,945
Lacosamide122$9,815
Levetiracetam319$9,720
DilantinPhenytoin Sodium Extended22$7,691
Memantine Hcl340$7,032
Lamotrigine187$5,635
RivastigmineRivastigmine Tartrate107$5,425
Carbamazepine ErCarbamazepine16$3,895

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Vimpat$1,436$56,36439 claims
SK Life Science, Inc.Xcopri$464$39,17132 claims
PfizerNurtec Odt, Eliquis, Dilantin$461$30,23552 claims
Neurelis, Inc.Valtoco$288$27,97520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 566 neurology providers in North Carolina.

Other neurology in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →